Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

rG17PE38, a novel immunotoxin target to gastric cancer with overexpressed CCK-2R.

Song J, Ren H, Li Y, Xu J, Kong H, Tong W, Zhou Y, Gao S, Liu Y, Hui Q, Peng Q, Lu S, Liu Z.

J Drug Target. 2013 May;21(4):375-82. doi: 10.3109/1061186X.2012.757770. Epub 2013 Jan 11.

PMID:
23311704
2.

A novel immunotoxin - rCCK8PE38 targeting of CCK-R overexpressed colon cancers.

Gao S, Song J, Chen F, Wang Q, Liu X, Ren H, Li Y, Meng X, Zhou Y, Lu S, Hu P, Tong W, Liu Z.

J Drug Target. 2015 Jun;23(5):462-8. doi: 10.3109/1061186X.2015.1009073. Epub 2015 Feb 12.

PMID:
25673265
3.

Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.

Kioi M, Seetharam S, Puri RK.

Mol Cancer Ther. 2008 Jun;7(6):1579-87. doi: 10.1158/1535-7163.MCT-07-2131.

4.

Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/PI3K/Akt pathway in human gastric cancer cells.

Xu W, Chen GS, Shao Y, Li XL, Xu HC, Zhang H, Zhu GQ, Zhou YC, He XP, Sun WH.

Cancer Lett. 2013 May 10;332(1):11-8. doi: 10.1016/j.canlet.2012.12.030. Epub 2013 Jan 29.

PMID:
23376640
5.

Expression, purification and characterization of recombinant toxins consisting of truncated gastrin 17 and pseudomonas exotoxin.

Feng XL, Liu XL, Lu SY, Ren HL, Li YS, Hu P, Wang Q, Tong W, Yan DM, Zhou Y, Zhang S, Jin W, Liu ZS.

Protein Pept Lett. 2015;22(2):193-201.

PMID:
25353354
7.

Gastrin suppresses growth of CCK2 receptor expressing colon cancer cells by inducing apoptosis in vitro and in vivo.

Müerköster S, Isberner A, Arlt A, Witt M, Reimann B, Blaszczuk E, Werbing V, Fölsch UR, Schmitz F, Schäfer H.

Gastroenterology. 2005 Sep;129(3):952-68.

PMID:
16143134
8.

Helicobacter pylori can induce heparin-binding epidermal growth factor expression via gastrin and its receptor.

Dickson JH, Grabowska A, El-Zaatari M, Atherton J, Watson SA.

Cancer Res. 2006 Aug 1;66(15):7524-31.

9.

Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.

Shinohara H, Morita S, Kawai M, Miyamoto A, Sonoda T, Pastan I, Tanigawa N.

J Surg Res. 2002 Feb;102(2):169-77.

PMID:
11796015
10.

A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.

Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Plückthun A, Stahel RA, Zangemeister-Wittke U.

Clin Cancer Res. 2003 Jul;9(7):2837-48. Erratum in: Clin Cancer Res. 2004 Apr 1;10(7):2579.

11.

Valine-286 residue in the third intracellular loop of the cholecystokinin 2 receptor exerts a pivotal role in cholecystokinin 2 receptor mediated intracellular signal transduction in human colon cancer cells.

Yu HG, Schäfer H, Mergler S, Müerköster S, Cramer T, Höcker M, Herzig KH, Schmidt WE, Schmitz F.

Cell Signal. 2005 Dec;17(12):1505-15.

PMID:
15951156
12.

High and low affinity receptors mediate growth effects of gastrin and gastrin-Gly on DLD-1 human colonic carcinoma cells.

Ahmed S, Budai B, Herédi-Szabó K, Farkas J, Tóth G, Murphy RF, Lovas S.

FEBS Lett. 2004 Jan 2;556(1-3):199-203.

13.

Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.

Behr TM, Béhé M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F, Becker W.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3124s-3138s.

PMID:
10541353
14.

Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.

Yang D, Kuan CT, Payne J, Kihara A, Murray A, Wang LM, Alimandi M, Pierce JH, Pastan I, Lippman ME.

Clin Cancer Res. 1998 Apr;4(4):993-1004.

15.

Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5.

Watson SA, Michaeli D, Grimes S, Morris TM, Crosbee D, Wilkinson M, Robinson G, Robertson JF, Steele RJ, Hardcastle JD.

Int J Cancer. 1995 Apr 10;61(2):233-40.

PMID:
7705954
16.

Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.

Zhou XX, Ji F, Zhao JL, Cheng LF, Xu CF.

J Gastroenterol Hepatol. 2010 Jul;25(7):1266-75. doi: 10.1111/j.1440-1746.2010.06287.x.

PMID:
20594254
17.

Pre-clinical evaluation of a new orally-active CCK-2R antagonist, Z-360, in gastrointestinal cancer models.

Grabowska AM, Morris TM, McKenzie AJ, Kumari R, Hamano H, Emori Y, Yoshinaga K, Watson SA.

Regul Pept. 2008 Feb 7;146(1-3):46-57. Epub 2007 Aug 23.

PMID:
17961733
18.

Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.

Kawasaki D, Emori Y, Eta R, Iino Y, Hamano H, Yoshinaga K, Tanaka T, Takei M, Watson SA.

Cancer Chemother Pharmacol. 2008 Apr;61(5):883-92. Epub 2007 Sep 28.

PMID:
17901954
20.

Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor-expressing cancers.

Wayua C, Low PS.

J Nucl Med. 2015 Jan;56(1):113-9. doi: 10.2967/jnumed.114.144998. Epub 2014 Dec 11.

Supplemental Content

Support Center